Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Filings indexed 1,392 across all filing types
Latest filing 2023-02-28 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-02-28 English
FORM 4 SUBMISSION
Director's Dealing
2023-02-28 English
FORM 4 SUBMISSION
Director's Dealing
2023-02-28 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 22, 2023, reporting the issuance of a press release announcing financial results for the three and twelve months ended December 31, 2022. The text explicitly states that the press release is furnished as an exhibit and that the Form 8-K is a current report. The document length is 3653 characters, which is relatively short and mainly serves as an announcement of the earnings release rather than containing detailed financial statements or analysis itself. According to the rules, such a document is classified as an Earnings Release (ER) since it is the initial announcement of quarterly/periodical financial results with key highlights only, and not a full interim or annual report. Therefore, the correct classification is ER with high confidence.
2023-02-22 English
FORM 4 SUBMISSION
Director's Dealing
2023-02-18 English
FORM 4 SUBMISSION
Director's Dealing
2023-02-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.